Patent Expiry
Patent/Exclusivity Expiry: QUILLIVANT XR
Other upcoming events for COLL
Phase 2 StartPhase 2 Start: Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind
Phase 3 ReadoutPhase 3 Topline: Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
Patent ExpiryPatent/Exclusivity Expiry: TROXYCA ER
Patent ExpiryPatent/Exclusivity Expiry: VIVITROL
Patent ExpiryPatent/Exclusivity Expiry: EMBEDA
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.